Key Trends and Insights into the Non-Muscle Invasive Bladder Cancer Market: Growth Rate and Opportunities to 2034
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the non-muscle invasive bladder cancer market grown in recent years?
The market size of non-muscle invasive bladder cancer has seen a robust growth in the recent past. The market is projected to escalate from $3.46 billion in 2024 to $3.67 billion in 2025, with a compound annual growth rate (CAGR) of 6.1%. Contributory factors for the growth during the historical period include an increase in the aging population, an escalation in healthcare expenditure, development in healthcare infrastructure, the rise of telemedicine, and an uptick in smoking rates.
How is the non-muscle invasive bladder cancer market size expected to evolve during the forecast period?
The market for non-muscle invasive bladder cancer is anticipated to experience significant growth in the forthcoming years. It is forecasted to rise to a size of $4.61 billion in the year 2029, expanding at a compound annual growth rate (CAGR) of 5.8%. The predicted growth during the forecast period is linked to the increasing use of targeted therapies, a greater focus on personalized medicine, escalated investments in the field of oncology research, the escalating demand for minimally invasive methods, and an upwards trend in chronic bladder cases. Key trends expected to characterize the forecast period are advancements in technology, precision medicine, artificial intelligence, telemedicine, and tools for digital health.
Get your non-muscle invasive bladder cancer market report here!
Which key drivers are propelling the non-muscle invasive bladder cancer market’s growth?
The swelling adoption of minimally invasive procedures is anticipated to bolster the rise of the non-muscle invasive bladder cancer market. These procedures use concise incisions and specialized tools to operate, causing less tissue trauma, decreased discomfort, quick recovery, and insignificant scarring in comparison to conventional, extensive surgery. The focus on such procedures is propelled by considerations including speedier recovery, better patient results, and an aging demographic, all of which together improve patient safety, contentment, and efficiency in healthcare. Non-muscle invasive bladder cancer enables such procedures by presenting localized treatments like transurethral resection and intravesical therapy, which accurately target the cancer cell, eliminating the requirement for invasive surgical interventions. For example, as per The Aesthetic Society in August 2023, American spending on aesthetic procedures exceeded $11.8 billion, marking a 2% rise from the previous year. Hence, the rising demand for minimally invasive procedures is promoting the growth of the non-muscle invasive bladder cancer market. With the growing emphasis on personalized medicine, the non-muscle invasive bladder cancer market is poised for growth. This concept revolves around tailoring medical treatments to match an individual’s genetic makeup, lifestyle, and environmental influences, ensuring more successful results. Expansion in this domain is propelled by advancements in genomic research, enhanced diagnostic tools, and the increasing need for highly targeted treatments. Non-muscle invasive bladder cancer empowers personalized medicine by facilitating treatment plans that are molded around specific tumor traits, genetic identifiers, and unique patient profiles. For example, the Personalized Medicine Coalition reported in February 2024 that the FDA issued approval for 16 novel personalized treatments for patients suffering from rare diseases in 2023, in contrast to six the previous year. Consequently, this is encouraging the expansion of the non-muscle invasive bladder cancer market.
What are the market segments in the non-muscle invasive bladder cancer industry?
The non-muscle invasive bladder cancer market covered in this report is segmented –
1) By Stage: Carcinoma In Situ (CIS), T1 Stage, Ta Stage
2) By Treatment: Immunotherapy, Chemotherapy, Surgery, Intravesical Therapy, Others Treatments
3) By Tumor: Low-Grade Tumours, High-Grade Tumours
4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Carcinoma In Situ (CIS): High-Grade CIS, Low-Grade CIS
2) By T1 Stage: T1a Stage (Superficial Tumors), T1b Stage (Invasive Into Lamina Propria)
3) By Ta Stage: Low-Grade Ta Stage, High-Grade Ta Stage
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20904&type=smp
Which leading companies are shaping the growth of the non-muscle invasive bladder cancer market?
Major companies operating in the non-muscle invasive bladder cancer market are Johnson & Johnson, Janssen Research & Development LLC, Merck & Co. Inc., AstraZeneca plc, Moderna Inc., Astellas Pharma US Inc., Ferring Pharmaceuticals, EMD Serono Inc., Fidia Farmaceutici SpA, Genentech Inc., Aura Biosciences Inc., UroGen Pharma Ltd., Asieris Pharmaceuticals, Protara Therapeutics Inc., Hamlet Pharma AB, Istari Oncology Inc., Heat Biologics Inc., Telormedix SA, Viventia Bio Inc., Theralase Technologies Inc., Vaxiion Therapeutics Inc., ImmunityBio Inc., Altor BioScience Corporation, SURGE Therapeutics Inc.
What emerging trends are influencing the growth of the non-muscle invasive bladder cancer market?
Major companies operating in the non-muscle invasive bladder cancer market are focusing on developing innovative products, such as immunotherapy, to improve treatment options and outcomes for patients. Immunotherapy involves harnessing the body’s immune system to detect and combat cancer cells by boosting or activating immune responses. For instance, in March 2024, ImmunityBio Inc., a US-based biotechnology company, received approval from the Food and Drug Administration (FDA) for ANKTIVA (N-803) in the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) featuring carcinoma in situ (CIS), with or without papillary tumors. This approval is based on promising clinical trial results, which show that ANKTIVA, when used in combination with Bacillus Calmette-Guérin (BCG), offers a viable treatment option for patients who have not responded to standard BCG therapy. ANKTIVA is a pioneering IL-15 agonist immunotherapy that works by enhancing the immune system, specifically stimulating natural killer (NK) cells and CD8+ killer T cells to target and destroy cancer cells.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20904
Which geographic areas are influencing the growth of the non-muscle invasive bladder cancer market?
North America was the largest region in the non-muscle invasive bladder cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-muscle invasive bladder cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Bladder Cancer Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report
Blood Cancer Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report
Cervical Cancer Drugs Global Global Market Report 2025
https://thebusinessresearchcompany.com/report/cervical-cancer-drugs-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
